Mortality in COVID‐19 hospitalizations with underlying hematologic malignancies in the United States

Sharma, Aditi; Deol, Abhinav; Singh, Vijendra K.

doi:10.1002/hon.3173

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The World Health Organization (WHO) declared the end of the COVID-19 pandemic ( 1 ) on 5 May 2023, but the SARS-CoV-2 infection remains an ongoing problem in certain settings, especially in immunocompromised (IC) patients ( 2 ). These patients, particularly those with hematologic malignancies, are at an increased risk of SARS-CoV-2-associated morbidity and mortality due to the immunologic deficits that limit primary prevention, treatment, and clearance of the virus ( 3 , 4 ). An impaired immune system impacts the natural course of the COVID-19 infection.…”

Section: Introductionmentioning

confidence: 99%

B-cell-depleted patients with persistent SARS-CoV-2 infection: combination therapy or monotherapy? A real-world experience

D’Abramo,

Vita,

Beccacece

et al. 2024

Front. Med.

View full text Add to dashboard Cite

ObjectivesThe aim of the study was to describe a cohort of B-cell-depleted immunocompromised (IC) patients with prolonged or relapsing COVID-19 treated with monotherapy or combination therapy.MethodsThis is a multicenter observational retrospective study conducted on IC patients consecutively hospitalized with a prolonged or relapsing SARS-CoV-2 infection from November 2020 to January 2023. IC COVID-19 subjects were stratified according to the monotherapy or combination anti-SARS-CoV-2 therapy received.ResultsEighty-eight patients were enrolled, 19 under monotherapy and 69 under combination therapy. The study population had a history of immunosuppression (median of 2 B-cells/mm3, IQR 1–24 cells), and residual hypogammaglobulinemia was observed in 55 patients. A reduced length of hospitalization and time to negative SARS-CoV-2 molecular nasopharyngeal swab (NPS) in the combination versus monotherapy group was observed. In the univariable and multivariable analyses, the percentage change in the rate of days to NPS negativity showed a significant reduction in patients receiving combination therapy compared to those receiving monotherapy.ConclusionIn IC persistent COVID-19 patients, it is essential to explore new therapeutic strategies such as combination multi-target therapy (antiviral or double antiviral plus antibody-based therapies) to avoid persistent viral shedding and/or severe SARS-CoV-2 infection.

show abstract

Section: Introductionmentioning

confidence: 99%